Alvotech Feed

	Est. tid*
2024-11-13	-	Kvartalsrapport 2024-Q3
2024-08-16	-	Kvartalsrapport 2024-Q2
2024-05-17	-	Kvartalsrapport 2024-Q1
2023-11-14	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-06-06	-	Årsstämma
2023-05-19	-	Kvartalsrapport 2023-Q1

Land	Island
Lista	Large Cap Iceland
Sektor	Hälsovård
Industri	Medicinteknik

2025-05-09 14:00:00 Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada

2025-05-09 14:00:00 Alvotech fundar með fjárfestum á heilbrigðisráðstefnu BofA Securities í Las Vegas og situr fyrir svörum

2025-05-09 14:00:00 Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada

2025-05-09 13:17:28 Viðskipti stjórnenda og tengdra aðila

2025-05-09 13:17:28 Transactions of Managers and Closely Associated Persons

2025-05-08 08:30:00 Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm 1190,00 ISK | +14,42%

2025-05-07 22:45:00 Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2025 og kynnir nýjustu áfanga í rekstri félagsins 1040,00 ISK | -0,48%

2025-05-07 22:45:00 Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update 1040,00 ISK | -0,48%

2025-05-07 11:00:00 Mögulegir tollar á innflutning lyfja til Bandaríkjanna hefðu hverfandi áhrif á tekjur Alvotech á árinu 1040,00 ISK | -0,48%

2025-05-07 11:00:00 Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 1040,00 ISK | -0,48%

2025-05-05 13:00:00 Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) 1070,00 ISK | +3,38%

2025-05-05 13:00:00 Selarsdi hliðstæðan fær fullan útskiptileika við frumlyfið Stelara í Bandaríkjunum 1070,00 ISK | +3,38%

2025-05-05 13:00:00 Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) 1070,00 ISK | +3,38%

2025-05-02 14:30:00 Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT 1035,00 ISK | +4,55%

2025-05-02 14:30:00 Alvotech kynnir uppgjör fyrsta ársfjórðungs 2025 8. maí nk. kl. 12 að íslenskum tíma 1035,00 ISK | +4,55%

2025-05-02 14:30:00 Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) 1035,00 ISK | +4,55%

2025-03-27 09:30:00 Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer 1450,00 ISK | -6,45%

2025-03-26 23:36:27 Alvotech birtir metuppgjör fyrir árið 2024, sem sýnir mikla tekjuaukningu og kynnir nýjar áherslur og áfanga í rekstri félagsins 1550,00 ISK | +0,16%

2025-03-26 23:36:27 Alvotech Reports Record Results for 2024 and Provides Business Update 1550,00 ISK | +0,16%

2025-03-26 23:34:45 Alvotech Reports Record Results for 2024 and Provides Business Update 1550,00 ISK | +0,16%

2025-03-26 09:30:00 Lyfjastofnun Bretlands samþykkir að taka til umsagnar umsókn um markaðsleyfi fyrir fyrirhugaða hliðstæðu við Xolair 1550,00 ISK | +0,16%

2025-03-26 09:30:00 UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) 1550,00 ISK | +0,16%

2025-03-20 08:00:00 Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production 1540,00 ISK | +3,01%

2025-03-20 08:00:00 Alvotech kaupir þróunarstarfsemi líftæknifyrirtækisins Xbrane í Svíþjóð 1540,00 ISK | +3,01%

2025-03-20 08:00:00 Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production 1540,00 ISK | +3,01%

2025-03-18 13:30:00 Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) samþykkir að taka til afgreiðslu umsókn um markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva 1515,00 ISK | +0,33%

2025-03-18 13:30:00 Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® 1515,00 ISK | +0,33%

2025-03-07 15:00:00 Alvotech fundar með fjárfestum á alþjóða heilbrigðisráðstefnu Barclays fjárfestingabankans í Miami og situr fyrir svörum 1520,00 ISK | +1,00%

2025-03-07 15:00:00 Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida 1520,00 ISK | +1,00%

2025-02-24 14:00:00 Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET 1675,00 ISK | -2,33%

2025-02-24 14:00:00 Alvotech heldur kynningarfund fyrir fjárfesta 27. mars 2025, eftir birtingu uppgjörs fyrir árið 2024 og fjórða ársfjórðung 1675,00 ISK | -2,33%

2025-02-21 12:00:00 Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. 1715,00 ISK | +3,63%

2025-02-21 12:00:00 Alvotech og Teva tilkynna að sala er hafin í Bandaríkjunum á Selarsdi (ustekinumab-aekn), hliðstæðu við líftæknilyfið Stelara 1715,00 ISK | +3,63%

2025-02-21 12:00:00 Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. 1715,00 ISK | +3,63%

2025-02-18 12:00:00 Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) 1785,00 ISK | -0,56%

2025-02-18 12:00:00 Alvotech og Teva tilkynna að umsókn um markaðsleyfi í Bandaríkjunum fyrir AVT06, fyrirhugaða hliðstæðu við augnlyfið Eylea, hafi verið tekin til umsagnar 1785,00 ISK | -0,56%

2025-02-18 12:00:00 Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) 1785,00 ISK | -0,56%

2025-01-27 12:00:00 Alvotech og Teva tilkynna að FDA hefur tekið til umsagnar umsókn um markaðsleyfi í Bandaríkjunum fyrir AVT05, fyrirhugaða hliðstæðu við Simponi og Simponi Aria (golimumab) 1795,00 ISK | -0,28%

2025-01-27 12:00:00 Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) 1795,00 ISK | -0,28%

2025-01-03 19:00:00 Alvotech birtir fjárhagsdagatal fyrir árið 2025 1840,00 ISK | -0,54%

2024-12-23 10:00:00 Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 1740,00 ISK | +5,78%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Kalender

Beskrivning

Alvotech

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden